Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell's Supervisory Board
13 Marzo 2024 - 11:41AM
Business Wire
Regulatory News:
MedinCell (Paris:MEDCL):
- Philippe Guy is a former Global leader of the Boston
Consulting Group's Healthcare Practice and member of BCG's
Executive Committee.
- He advised many global pharmaceutical and biotech companies
on a large range of topics such as corporate and business unit
level strategy, R&D process optimization and organization,
commercial go-to-market strategies, as well as large-scale
transformation and post-merger/acquisition integrations.
- Philippe Guy has been actively participated to the growth of
MedinCell as a board member, leading the Audit Committee during and
post the IPO, and championing the integration of sustainable
practices at the board level by creating and leading the ESG
Committee.
- As Chairman, he will leverage his vast experience to support
the company management in crafting and implementing MedinCell's
strategy
“After reaching the commercial stage with significant potential
revenues on the horizon, MedinCell stands at a pivotal moment. Our
opportunity is to anticipate and prepare for the future. Many
levers exist to achieve sustainable and profitable growth:
advancing our R&D pipeline, forging new partnerships, driving
technology innovation. I am incredibly excited to share my
expertise and contribute to supporting MedinCell's teams while
preserving the mission and company model that have been key to our
success”, states Philippe Guy.
With over 33 years of distinguished service at Boston Consulting
Group (BCG), primarily within the healthcare sector, Philippe Guy
has built a deep global expertise, working from Europe (London,
Paris, Zurich), Japan, and North America. During his tenure, he
played a pivotal role in developing BCG's Healthcare Practice Area
across these regions. His leadership extended to steering the
Global Healthcare Practice for nine years, further amplifying his
impact on the industry. Additionally, he was peer-selected to
represent all sector and functional practices on BCG's global
Executive Committee, reflecting his broad strategic vision and
leadership.
Philippe Guy is engaged on a pro-bono basis with the Foundation
de la Mer, where his efforts are focused on scaling up its
international impact. This includes contributing to key United
Nations negotiations and facilitating the formation of coalitions
among like-minded European foundations.
Besides MedinCell, Philippe also serves on the Board of Moleac,
a Singapore-based company helping patients with brain injuries and
neurological conditions.
Philippe Guy multifaceted career trajectory reflects a blend of
strategic leadership in healthcare and a deep-seated commitment to
ESG.
About MedinCell
MedinCell is a clinical- and commercial-stage biopharmaceutical
company developing long-acting injectable drugs in many therapeutic
areas. Our innovative treatments aim to guarantee compliance with
medical prescriptions, to improve the effectiveness and
accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY™ (BEPO technology is
licensed to Teva under the name SteadyTeq™).
We collaborate with leading pharmaceutical companies and
foundations to improve global health through new treatment options.
Based in Montpellier, MedinCell currently employs more than 140
people representing more than 25 different nationalities.
UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.medincell.com
This press release contains forward-looking statements,
including statements regarding Company’s expectations for (i) the
timing, progress and outcome of its clinical trials; (ii) the
clinical benefits and competitive positioning of its product
candidates; (iii) its ability to obtain regulatory approvals,
commence commercial production and achieve market penetration and
sales; (iv) its future product portfolio; (v) its future partnering
arrangements; (vi) its future capital needs, capital expenditure
plans and ability to obtain funding; and (vii) prospective
financial matters regarding our business. Although the Company
believes that its expectations are based on reasonable assumptions,
any statements other than statements of historical facts that may
be contained in this press release relating to future events are
forward-looking statements and subject to change without notice,
factors beyond the Company's control and the Company's financial
capabilities.
These statements may include, but are not limited to, any
statement beginning with, followed by or including words or phrases
such as "objective", "believe", "anticipate", “expect”, "foresee",
"aim", "intend", "may", "anticipate", "estimate", "plan",
"project", "will", "may", "probably", “potential”, "should",
"could" and other words and phrases of the same meaning or used in
negative form. Forward-looking statements are subject to inherent
risks and uncertainties beyond the Company's control that may, if
any, cause actual results, performance, or achievements to differ
materially from those anticipated or expressed explicitly or
implicitly by such forward-looking statements. A list and
description of these risks, contingencies and uncertainties can be
found in the documents filed by the Company with the Autorité des
Marchés Financiers (the "AMF") pursuant to its regulatory
obligations, including the Company's registration document,
registered with the AMF on September 4, 2018, under number I.
18-062 (the "Registration Document"), as well as in the documents
and reports to be published subsequently by the Company. In
particular, readers' attention is drawn to the section entitled
"Facteurs de Risques" on page 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the
Company speak only as of the date they are made. Except as required
by law, the Company does not undertake any obligation to publicly
update these forward-looking statements or to update the reasons
why actual results could differ materially from those anticipated
by the forward-looking statements, including in the event that new
information becomes available. The Company's update of one or more
forward-looking statements does not imply that the Company will
make any further updates to such forward-looking statements or
other forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements.
This press release is for information purposes only. The
information contained herein does not constitute an offer to sell
or a solicitation of an offer to buy or subscribe for the Company's
shares in any jurisdiction, in particular in France. Similarly,
this press release does not constitute investment advice and should
not be treated as such. It is not related to the investment
objectives, financial situation, or specific needs of any
recipient. It should not deprive the recipients of the opportunity
to exercise their own judgment. All opinions expressed in this
document are subject to change without notice. The distribution of
this press release may be subject to legal restrictions in certain
jurisdictions. Persons who come to know about this press release
are encouraged to inquire about, and required to comply with, these
restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240313495827/en/
David Heuzé - Head of Communications
david.heuze@medincell.com / +33 (0)6 83 25 21 86
Head of US Financial Strategy & IR Grace Kim
grace.kim@medincell.com / +1 (646) 991-4023
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Investor Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Medincell (EU:MEDCL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Medincell (EU:MEDCL)
Gráfica de Acción Histórica
De May 2023 a May 2024